441 Results for "

Pharmacokinetic booster

" in MedChemExpress (MCE) Product Catalog:
Products (441)

441 Results for "Pharmacokinetic booster" in MCE Product Catalog:

23
23 Publications Verification
Cat. No.: HY-130251
CAS No.: 2227149-22-4
Purity:  99.87%
DS18561882 is a highly potent, isozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with an IC50 value of 0.0063 μM. DS18561882 also has inhibitory effect on MTHFD1 (IC50=0.57 μM). DS18561882 exhibits a good oral pharmacokinetic profile .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-125840
CAS No.: 1672668-24-4
Purity:  99.85%
Synonyms: PT2977; MK-6482
Research Areas:  

Cancer

Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-U00418
CAS No.: 1698055-85-4
Target:  

Ras

Research Areas:  

Cancer

ARS-1620 is an atropisomeric selective KRAS G12C inhibitor with desirable pharmacokinetics.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-10493
CAS No.: 1004316-88-4
Purity:  99.49%
Synonyms: GS-9350
Target:  

Cytochrome P450 HIV

Research Areas:  

Infection Cancer

Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-137207
CAS No.: 864388-65-8
Purity:  99.88%
Target:  

PERK

Research Areas:  

Neurological Disease

MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-134923
CAS No.: 2412270-22-3
Purity:  99.98%
Target:  

Autophagy

Research Areas:  

Neurological Disease

CA77.1 is a potent, brain-penetrant and orally active chaperone-mediated autophagy (CMA) activator with favorable pharmacokinetics. CA77.1 is a derivative of AR7 (HY-101106) and can increase the expression of the lysosomal receptor LAMP2A in?lysosomes. CA77.1 improves behavior and neuropathology in PS19 mice model and can be used for alzheimer's?disease research .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15023
CAS No.: 900510-03-4
Purity:  99.95%
Synonyms: PF-3274167
Target:  

Oxytocin Receptor

Research Areas:  

Endocrinology

Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents [1][2].
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-109142
CAS No.: 1422500-60-4
Purity:  95.51%
Synonyms: AK0529; RO-0529
Target:  

RSV

Research Areas:  

Infection

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-114778
CAS No.: 1358715-18-0
Purity:  99.96%
Synonyms: SHR3162; Fuzuloparib
Target:  

PARP

Research Areas:  

Cancer

Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-151563A
Purity:  99.56%
Target:  

Deubiquitinase

Research Areas:  

Cancer

OTUB1/USP8-IN-1 TFA is the TFA salt form of OTUB1/USP8-IN-1 (HY-151563). OTUB1/USP8-IN-1 TFA is a dual inhibitor for OTUB1/USP8, IC50 for OTUB1 and USP8 is 0.17 and 0.28 nM, respectively. OTUB1/USP8-IN-1 TFA inhibits proliferation of NSCLC cells. OTUB1/USP8-IN-1 TFA exhibits good pharmacokinetic characters in ICR mouse, and exhibits antitumor activity in H1975 xenograft mouse model .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-125021
CAS No.: 2143542-28-1
Purity:  99.31%
2BAct is a highly selective, orally active, and CNS-penetrant eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18071A
CAS No.: 1422252-46-7
Research Areas:  

Cardiovascular Disease

BI-9627 hydrochloride is a potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor (IC50 = 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays). BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride decreases autophagy in HTR-8/SVneo cells. BI-9627 hydrochloride can significantly reduce the pHi of human sperm and partially reverse the effect of DMA. BI-9627 hydrochloride prolongs Ca 2+ recovery time in KO hiPSC-CMs. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18071
CAS No.: 1204329-34-9
Research Areas:  

Cardiovascular Disease

BI-9627, a chemical probe, is a potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor (IC50 = 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays). BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 decreases autophagy in HTR-8/SVneo cells. BI-9627 can significantly reduce the pHi of human sperm and partially reverse the effect of DMA. BI-9627 prolongs Ca 2+ recovery time in KO hiPSC-CMs. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-138171
CAS No.: 2089251-33-0
Purity:  99.50%
Target:  

Liposome

Research Areas:  

Others

Lipid 5 is an amino lipid that affords efficient mRNA delivery in rodent and primate models. Lipid 5 shows optimal pharmacokinetics and non-toxic side effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18353
CAS No.: 1207358-59-5
Target:  

mTOR

Research Areas:  

Cancer

mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15738
CAS No.: 778277-15-9
Purity:  99.95%
Target:  

Bcr-Abl

Research Areas:  

Cancer

GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99250
CAS No.: 1133766-06-9
Synonyms: MetMAb

Target:  

c-Met/HGFR

Research Areas:  

Neurological Disease Cancer

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14305A
CAS No.: 912806-16-7
Purity:  98.90%
Target:  

p38 MAPK Autophagy

Research Areas:  

Inflammation/Immunology

BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132296
CAS No.: 2743427-26-9
Purity:  99.26%
Target:  

FAK PROTACs

Research Areas:  

Cancer

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-139602
CAS No.: 2135640-93-4
Purity:  98.46%
Research Areas:  

Infection

(+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .
loading...
    loading...